- Home
- PAVS vs KPTI Comparison
PAVS vs KPTI Comparison
Compare PAVS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVS
- KPTI
- Stock Information
- Founded
- PAVS 2004
- KPTI 2008
- Country
- PAVS United States
- KPTI United States
- Employees
- PAVS N/A
- KPTI N/A
- Industry
- PAVS Medicinal Chemicals and Botanical Products
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- PAVS Health Care
- KPTI Health Care
- Exchange
- PAVS Nasdaq
- KPTI Nasdaq
- Market Cap
- PAVS 89.6M
- KPTI 44.5M
- IPO Year
- PAVS 2019
- KPTI 2013
- Fundamental
- Price
- PAVS $0.92
- KPTI $4.74
- Analyst Decision
- PAVS
- KPTI Strong Buy
- Analyst Count
- PAVS 0
- KPTI 7
- Target Price
- PAVS N/A
- KPTI $45.43
- AVG Volume (30 Days)
- PAVS 5.0K
- KPTI 146.2K
- Earning Date
- PAVS 07-31-2025
- KPTI 08-05-2025
- Dividend Yield
- PAVS N/A
- KPTI N/A
- EPS Growth
- PAVS N/A
- KPTI N/A
- EPS
- PAVS N/A
- KPTI N/A
- Revenue
- PAVS $6,613,273.00
- KPTI $142,126,000.00
- Revenue This Year
- PAVS N/A
- KPTI $2.09
- Revenue Next Year
- PAVS N/A
- KPTI $12.90
- P/E Ratio
- PAVS N/A
- KPTI N/A
- Revenue Growth
- PAVS 2.50
- KPTI 1.19
- 52 Week Low
- PAVS $0.32
- KPTI $3.51
- 52 Week High
- PAVS $1.50
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- PAVS 54.80
- KPTI 41.48
- Support Level
- PAVS $0.82
- KPTI $4.23
- Resistance Level
- PAVS $0.98
- KPTI $5.14
- Average True Range (ATR)
- PAVS 0.04
- KPTI 0.38
- MACD
- PAVS 0.02
- KPTI 0.04
- Stochastic Oscillator
- PAVS 79.76
- KPTI 24.45
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.